CTRI vs MGEE

CTRI exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9, indicating robust operational improvements. However, this fundamental health is completely decoupled from its market valuation, with the current price of $34.74 trading at a massive premium to both the Graham Number ($6.98) and Intrinsic Value ($7.38). Despite explosive YoY earnings growth, the company has missed analyst estimates in four consecutive quarters, and the current P/E of 138.96 is unsustainable. The stock is currently trading at its 52-week high while analyst target prices ($31.34) have already fallen below the current market price.

MGEE presents a dichotomy between superior operational efficiency and poor valuation metrics. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts profit margins and ROE significantly above sector averages, the stock is trading at a substantial premium to its Graham Number ($54.65) and Intrinsic Value ($54.50). The technical trend is currently bearish (0/100), and a consistent history of missing earnings estimates suggests limited near-term catalysts for price appreciation despite a conservative debt profile.